H. Pylori Eradication on Healing of Iatrogenic Gastric Ulcer by Endoscopic Mucosal Resection
Primary Purpose
Ulcer
Status
Unknown status
Phase
Phase 4
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Lansoprazole (proton pump inhibitor), amoxicillin, clarythromycin
Lansoprazole (proton pump inhibitor), placebo
Sponsored by
About this trial
This is an interventional treatment trial for Ulcer focused on measuring endoscopic mucosal resection, iatrogenic
Eligibility Criteria
Inclusion Criteria:
- 30 - 75 years old
- Early gastric cancer (< 3 cm in size, mucosa confined, differentiated type) or gastric adenoma (< 3 cm in size)
- Helicobacter pylori positive
Exclusion Criteria:
- Medication of anti-secretory drugs (proton pump inhibitors, H2-receptor antagonists, antacid, bismuth compound)
- History of Helicobacter pylori eradication
- History of gastric surgery or other cancers
- Major comorbidities
- Medication of ASA, NSAIDS, steroids, anti-coagulants
Sites / Locations
- National Cancer Center KoreaRecruiting
- Asan Medical CenterRecruiting
- Korea University HospitalRecruiting
- Seoul National University HospitalRecruiting
- Soonchunhyang University HospitalRecruiting
- Yonsei University Severance HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Eradication
No eradication
Arm Description
Helicobacter pylori eradication
No eradication for Helicobacter pylori
Outcomes
Primary Outcome Measures
ulcer healing rate by endoscopic assessment
Secondary Outcome Measures
ulcer reduction rate by endoscopic assessment
Full Information
NCT ID
NCT00926809
First Posted
June 23, 2009
Last Updated
June 24, 2009
Sponsor
Korean College of Helicobacter and Upper Gastrointestinal Research
1. Study Identification
Unique Protocol Identification Number
NCT00926809
Brief Title
H. Pylori Eradication on Healing of Iatrogenic Gastric Ulcer by Endoscopic Mucosal Resection
Official Title
Helicobacter Pylori Eradication Therapy on the Healing of Iatrogenic Gastric Ulcer After Endoscopic Mucosal Resection of Gastric Neoplastic Lesions: a Multicenter, Randomized, Double Blind, and Placebo Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
June 2009
Overall Recruitment Status
Unknown status
Study Start Date
September 2008 (undefined)
Primary Completion Date
September 2010 (Anticipated)
Study Completion Date
December 2010 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
Korean College of Helicobacter and Upper Gastrointestinal Research
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study will evaluate the effect of Helicobacter pylori eradication therapy on the healing of iatrogenic gastric ulcer caused by endoscopic mucosal resection of gastric neoplastic lesions and is a multicenter, randomized, double blind, and placebo controlled trial.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ulcer
Keywords
endoscopic mucosal resection, iatrogenic
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
232 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Eradication
Arm Type
Active Comparator
Arm Description
Helicobacter pylori eradication
Arm Title
No eradication
Arm Type
Placebo Comparator
Arm Description
No eradication for Helicobacter pylori
Intervention Type
Drug
Intervention Name(s)
Lansoprazole (proton pump inhibitor), amoxicillin, clarythromycin
Intervention Description
Lansoprazole, Amoxicillin 1000 mg, Clarithromycin 500 mg
Intervention Type
Drug
Intervention Name(s)
Lansoprazole (proton pump inhibitor), placebo
Intervention Description
Lansoprazole, Amoxicillin placebo, Clarythromycin placebo
Primary Outcome Measure Information:
Title
ulcer healing rate by endoscopic assessment
Time Frame
8 weeks
Secondary Outcome Measure Information:
Title
ulcer reduction rate by endoscopic assessment
Time Frame
8 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
30 - 75 years old
Early gastric cancer (< 3 cm in size, mucosa confined, differentiated type) or gastric adenoma (< 3 cm in size)
Helicobacter pylori positive
Exclusion Criteria:
Medication of anti-secretory drugs (proton pump inhibitors, H2-receptor antagonists, antacid, bismuth compound)
History of Helicobacter pylori eradication
History of gastric surgery or other cancers
Major comorbidities
Medication of ASA, NSAIDS, steroids, anti-coagulants
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ho June Song, Ph.D
Phone
82-2-3010-3916
Email
hojunesong@yahoo.co.kr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hyun Chae Jung
Organizational Affiliation
Korean College of Helicobacter and Upper Gastrointestinal Research
Official's Role
Principal Investigator
Facility Information:
Facility Name
National Cancer Center Korea
City
Goyang
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Il Ju Choi
Facility Name
Asan Medical Center
City
Seoul
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ho June Song
Email
hjsong@amc.seoul.kr
First Name & Middle Initial & Last Name & Degree
Hwoon-Yong Jung
Facility Name
Korea University Hospital
City
Seoul
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hoon Jae Chun
Facility Name
Seoul National University Hospital
City
Seoul
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sang Gyun Kim
First Name & Middle Initial & Last Name & Degree
Hyun Chae Jung
Facility Name
Soonchunhyang University Hospital
City
Seoul
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Joo Young Cho
Facility Name
Yonsei University Severance Hospital
City
Seoul
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yong Chan Lee
First Name & Middle Initial & Last Name & Degree
Jae Hee Cheon
12. IPD Sharing Statement
Learn more about this trial
H. Pylori Eradication on Healing of Iatrogenic Gastric Ulcer by Endoscopic Mucosal Resection
We'll reach out to this number within 24 hrs